Galcanezumab

Drug Profile

Galcanezumab

Alternative Names: CGRP antibody for prevention of migraine - Eli Lilly; LY2951742

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cluster headache
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cluster headache; Migraine
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 07 Nov 2016 Eli Lilly plans a phase III trial for Migraine in Japan (SC) (NCT02959190)
  • 01 Nov 2016 Phase-II clinical trials in Migraine in Japan (SC) (NCT02959177)
  • 26 Sep 2016 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 16th World Congress on Pain (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top